Diagnostic and Interventional Imaging · Nov 11, 2026
Balancing harm minimization and oncological safety in MRI-informed prostate cancer screening
By Hamm CA, Alaro S, Nitschke LV et al.
Purpose Risk-adapted prostate cancer screening is endorsed by international healthcare organizations. However, oncological safety and harm minimization in magnetic resonance imaging (MRI)–informed screening lack validation. The purpose of this study was to evaluate the diagnostic utility of an MRI-first screening strategy for detecting grade group (GG) ≥ 2 prostate cancer. Materials and methods This prospective, multi-site study recruited men between the ages of 50 and 69 from three public service providers in Berlin. Eligible participants underwent MRI and serum prostate-specific antigen (PSA) testing at two imaging centers. Prostate biopsy was recommended following MRI positivity (score 4–5) or serum PSA ≥ 4 ng/mL (high-risk). MRI-negative men (score 1–2) with PSA < 3 ng/mL were discharged (low-risk), while men with an MRI score of 3 or a PSA of 3–4 ng/mL were actively followed and invited to repeat screening after 1 year (indeterminate-risk). The primary outcome was the proportion of risk groups and GG ≥ 2 prostate cancer detected using MRI alone or combined with PSA. Results Of 587 screened men, 566 (mean age, 57.2 ± 4.7 years [SD]; range: 50–69 years) were eligible, and 552 underwent both screening tests. Of these, 78/552 (14.1%; 95% CI: 11.5–17.3), 51/552 (9.2%; 95% CI: 7.1–11.9), and 423/552 (76.6%; 95% CI: 72.9–80.0) were classified as high-, indeterminate-, and low-risk, respectively. PSA testing alone would have missed 9/18 (50.0%) and 7/18 (38.9%) of screen-detected GG ≥ 2 prostate cancers at ≥ 4 and ≥ 3 ng/mL thresholds. Biopsying MRI-positive men detected 17/18 (94.4%) of GG ≥ 2 prostate cancers. A PSA-gated (≥ 3 ng/mL) MRI-informed strategy demonstrated excellent strategy compliance (13/13 [100.0%]), could protect 24/27 (88.9%) from unproductive biopsies and GG1 overdiagnosis, and detect 10/18 (55.6%) of GG ≥ 2 prostate cancers. Conclusion MRI-first screening demonstrates high oncological safety for GG ≥ 2 prostate cancer but increases overdiagnosis and biopsy rates. PSA-gated MRI-informed strategies may reduce harm while maintaining acceptable detection rates.
doi.org/10.1016/j.diii.2026.11.001Open accessPubMed 43015237Biomarkers